Related Experiment Videos
Primary hyperparathyroidism and monoclonal gammopathy
D S Rao1, R Antonelli, K R Kane
1Bone and Mineral Division, Henry Ford Hospital, Detroit, MI 48202.
Henry Ford Hospital Medical Journal
|January 1, 1991
Summary
Primary hyperparathyroidism and monoclonal gammopathy rarely coexist. This study suggests their concurrence in patients is likely due to chance, not a direct causal link.
Area of Science:
- Endocrinology
- Hematology
- Oncology
Background:
- Primary hyperparathyroidism is a common endocrine disorder.
- Monoclonal gammopathies, including multiple myeloma, are hematologic malignancies.
- The coexistence of these two conditions is infrequently reported.
Observation:
- This study reviewed four patients with coexisting primary hyperparathyroidism and monoclonal gammopathy seen between 1976 and 1988.
- An additional patient with primary hyperparathyroidism and multiple myeloma in remission was also observed.
- These cases constituted approximately 1% of all primary hyperparathyroidism cases during the study period.
Findings:
- The concurrence of primary hyperparathyroidism and monoclonal gammopathy is rare.
- The study posits that the co-occurrence is likely a result of chance.
- Literature review and statistical estimation support the chance occurrence hypothesis.
Implications:
- Understanding the low probability of this coexistence is crucial for clinical practice.
- Clinicians should consider both conditions when evaluating patients.
- Further research may elucidate any subtle associations, though chance remains the primary explanation.